共 63 条
[1]
Houzen H(2018)Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan Eur J Neurol 25 334-9
[2]
Kondo K(2012)Genetic and environmental backgrounds responsible for the changes in the phenotype of MS in japanese subjects Mult Scler Relat Disord 1 188-95
[3]
Horiuchi K(2018)Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Lancet Neurol 17 162-73
[4]
Niino M(2018)Multiple sclerosis N Eng J Med 378 169-80
[5]
Kira J(2018)Japan: health system review Health Syst Transit 8 1-228
[6]
Thompson AJ(2017)Efficacy, safety, and pharmacokinetics of natalizumab in japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study Mult Scler Relat Disord 11 25-31
[7]
Banwell BL(2017)Safety and efficacy of natalizumab in japanese patients with relapsing-remitting multiple sclerosis: open-label extension study of a phase 2 trial Neurol Ther 6 39-55
[8]
Barkhof F(2017)Safety and effectiveness of natalizumab: first report of interim results of post-marketing surveillance in Japan Neurol Ther 6 197-211
[9]
Reich DS(1983)Rating neurologic impairment in multiple sclerosis Neurology 33 1444-52
[10]
Lucchinetti CF(2013)A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification J Clin Virol 57 141-6